Lab Lowdown for November 6, 2026

This edition covers original announcements published from Saturday, Oct. 31, through Friday morning, Nov. 6, 2026. The week’s laboratory news moved across diagnostic preparedness, genomics at scale, informatics, analytical separations, and pathology digitization. Here are six developments worth a quick catch-up, with company projections and regulated-use boundaries kept in view.

Cepheid’s Multiplex PCR Panel Gains FDA Clearance

Published Nov. 3: Cepheid announced that the FDA cleared its Xpert Hemorrhagic Fever Panel, a qualitative multiplex PCR assay that detects Ebola viruses, Marburg virus, Lassa virus, and Crimean-Congo hemorrhagic fever virus from one sample. The FDA’s 510(k) database records the decision on Oct. 30. Cepheid says the closed cartridge runs on GeneXpert Dx systems in about 61 minutes and includes a viral-inactivation step.

A single automated assay can help laboratories distinguish high-consequence infections that may present with overlapping early symptoms, but the clearance does not replace clinical assessment, epidemiologic information, biosafety controls, public-health reporting, or confirmatory and referral procedures. The Ebola result also does not differentiate among the four covered Ebola virus species.

Original Cepheid announcement | FDA 510(k) record | LabPress coverage

Phenotype Matching Moves Into a Rare-Disease Genomics Workbench

Published Nov. 5: ARUP Laboratories and GenomOncology announced a multiyear license that brings ARUP’s Jalapheno phenotype-matching tool into the GO Pathology Workbench. Developed with the University of Utah, Jalapheno converts patient features recorded as Human Phenotype Ontology terms into gene-level matching scores for exome, genome, and large germline-panel analysis.

The integration could reduce handoffs by putting phenotype prioritization, annotation, classification, and reporting in one environment. GenomOncology is also adding optional AI workflows that can classify prioritized variants and draft interpretations. Those outputs remain preliminary software assistance: a qualified laboratory reviewer must edit and approve the interpretation, and laboratories still need algorithm validation, version control, and traceable decision records.

Original ARUP announcement | LabPress coverage

Singapore’s Precision-Medicine Program Adds Automated Sample Preparation

Published Nov. 3: QIAGEN said it will provide QIAsprint Connect DNA extraction and QIAseq FX DNA library-preparation technology for SG-INSIGHT, a cohort in Phase III of Singapore’s National Precision Medicine program. The project, led by Lucence with Ultima Genomics and coordinated by Precision Health Research, Singapore, is part of a broader phase intended to reach about 450,000 residents.

For laboratory teams, the announcement is a practical reminder that large population-genomics programs depend as much on preanalytical consistency, barcoding, audit trails, and library-preparation throughput as on sequencer output. This is a study workflow deployment, not evidence of a newly cleared clinical test, and QIAGEN’s performance descriptions are company-reported.

Original QIAGEN announcement | LabPress coverage

LabCollector Connects Laboratory Jobs With HubSpot Records

Published Nov. 5: AgileBio added a two-way HubSpot integration to LabCollector Lab Service Manager. A laboratory can configure a HubSpot deal, ticket, order, or custom object to create a laboratory job, map line items to tests by product SKU, and return the job number, status, result summary, portal link, or private report to the CRM.

The connection may reduce duplicate entry and give client-facing teams more timely visibility into work in progress. It also creates a new integration boundary that laboratories should validate. SKU mapping, permissions, attachment handling, audit trails, exception paths, and change control all matter before production use. Availability and workflow benefits are vendor-reported.

Original AgileBio and LabCollector announcement | LabPress coverage

Waters Acquires MOBILion’s Ion-Mobility Technology

Published Nov. 3: Waters acquired MOBILion Systems, adding Structures for Lossless Ion Manipulations, or SLIM, to its mass spectrometry portfolio. SLIM separates ions by size, shape, and charge before mass analysis. Financial terms were not disclosed. Waters said it plans to pair the technology with its Xevo MRT mass spectrometer and waters_connect software.

An orthogonal ion-mobility step can help proteomics laboratories resolve features that liquid chromatography and mass spectrometry alone may not separate cleanly. Waters’ statements about future coverage, sensitivity, throughput, and AI-enabled workflows are projections. Laboratories will need integration timelines, representative performance data, method-transfer details, service requirements, and data-compatibility information before evaluating a combined platform.

Original Waters announcement | LabPress coverage

Agilent Completes Its Proscia Digital-Pathology Acquisition

Published Nov. 4: Agilent Technologies completed its acquisition of Proscia for $240 million in cash at closing, plus as much as $30 million tied to future performance milestones. Proscia is now part of Agilent’s Life Sciences and Diagnostics Markets Group. The deal adds the vendor-agnostic Concentriq digital-pathology platform to Agilent’s existing pathology instruments and reagents.

The transaction could simplify integration across slide digitization, case management, analysis, and pathology data, but the companies’ operating benefits remain prospective. Clinical laboratories should confirm the intended use of each component, because Proscia distinguishes its FDA-cleared Concentriq AP-Dx configuration from research-use platforms and AI applications. Interoperability, cybersecurity, validation, migration, data governance, and support road maps remain central purchasing questions.

Original Agilent announcement | LabPress coverage